Deutsche Bank Rese… Analysts Give Evotec (ETR:EVT) a €33.00 Price Target

Evotec (ETR:EVTGet Rating) has been given a €33.00 ($35.87) price target by equities researchers at Deutsche Bank Rese… in a note issued to investors on Wednesday, Borsen Zeitung reports. Deutsche Bank Rese…’s price target would suggest a potential upside of 31.74% from the stock’s previous close.

A number of other research analysts also recently issued reports on EVT. Jefferies Financial Group set a €55.00 ($59.78) target price on shares of Evotec in a research report on Wednesday, March 2nd. Berenberg Bank set a €47.00 ($51.09) target price on shares of Evotec in a research report on Monday, February 7th. Royal Bank of Canada set a €43.00 ($46.74) target price on shares of Evotec in a research report on Tuesday. Deutsche Bank Aktiengesellschaft set a €39.00 ($42.39) target price on shares of Evotec in a research report on Monday, February 7th. Finally, Warburg Research set a €43.00 ($46.74) price target on Evotec in a research note on Tuesday.

Evotec stock traded down €1.84 ($2.00) during trading hours on Wednesday, reaching €25.05 ($27.23). 960,893 shares of the company’s stock traded hands, compared to its average volume of 1,360,000. The company has a debt-to-equity ratio of 50.43, a quick ratio of 2.22 and a current ratio of 2.48. Evotec has a fifty-two week low of €23.26 ($25.28) and a fifty-two week high of €45.83 ($49.82). The firm has a market capitalization of $4.43 billion and a price-to-earnings ratio of 16.74. The firm’s 50 day moving average is €27.48 and its 200-day moving average is €35.88.

Evotec Company Profile (Get Rating)

Evotec SE operates as a drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as neuronal diseases, diabetes and complications of diabetes, pain, inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare diseases, and women's health.

Featured Stories

Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.